Jidesheng Snake Pills as Adjunctive Therapy for Snakebite: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Zengwen Ma, Yalan Song, Zheng Huang et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed randomized evidence for Jidesheng Snake Pills as adjunctive treatment for snakebite. Five unique trials involving 458 participants were included. Because definitions of clinical response differed, the authors did not calculate a primary pooled response estimate; a post hoc harmonized analysis found an estimate of 1.14 (95% confidence interval, 0.97 to 1.35; I 2 = 7.9%). Swelling-resolution time and hospital stay were shorter on average, but analyses were uncertain and certainty was very low for every principal outcome. The authors conclude that clinical benefit remains uncertain.
Key findings
- The post hoc harmonized clinical-response estimate was 1.14 (95% confidence interval, 0.97 to 1.35; I 2 = 7.9%).
- Swelling-resolution time was shorter by 1.64 days (95% confidence interval, 3.05 to 0.24 days shorter; I 2 = 90.0%); every leave-one-out robust interval crossed the null.
- Hospital stay was shorter by 1.49 days (95% confidence interval, 2.38 to 0.61 days shorter; I 2 = 0%).
- Certainty was very low for every principal outcome.
Why it matters
Snakebite treatment evidence can be difficult to interpret when trials use different outcome definitions and interventions. This review highlights that apparent reductions in swelling-resolution time and hospital stay do not establish a reliable clinical benefit: the evidence came from few trials, was heterogeneous, and was rated very low certainty. Clearer, patient-important outcomes and structured safety assessment are needed to inform decisions.
What to keep in mind
The evidence comprised five trials and was described as methodologically weak, clinically heterogeneous, and indirect. Response definitions differed, and leave-one-out analyses for swelling-resolution time crossed the null.